BioWorld

Sep. 17, 2009

Neurocrine Snares $75M CEFF to Hunt for Products to License

Neurocrine Biosciences Inc. has secured a commitment from Kingsbridge Capital Ltd. to purchase shares in the company through a warrant-free equity financing that would provide up to $75 million over three years. (BioWorld Today) Read More

Pervasis Tackling PAD with $17M Round; Seeks Vascugel Partner

Commercialization Conundrum: Partnering vs. Building a FIPCO

Despite Concerns, Panel Favors Auxilium's Xiaflex in Dupuytren's

IPOs on Parade: Anthera Seeks $70M to Fund Cardio Studies

CMS Bundling Rule: Bad News for Amgen Now, Genzyme Later

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...